Clinical Trial Detail

NCT ID NCT03269669
Title Obinutuzumab With or Without PI3K-delta Inhibitor TGR-1202, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

follicular lymphoma

Therapies

Cyclophosphamide + Doxorubicin + Obinutuzumab + Prednisone + Vincristine Sulfate

Lenalidomide + Obinutuzumab

Obinutuzumab + Umbralisib

Prednisone

Age Groups: adult senior

No variant requirements are available.